In conclusion, this additive network meta-analysis of almost 25,500 patients across eight large, randomized trials provides comprehensive evidence (moderate quality of evidence) that the combination of steroid and non-steroid MRA, SGLT2i, and GLP-1 RA was the most effective strategy for lowering the risk of cardiovascular death or HF hospitalization in patients with HFpEF. This evidence concerns the gene GLP1R and hydrops fetalis.